Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1)
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the feasibility of combining two drugs, Tarceva (an anti-EGFR
agent), and Rapamycin (an mTOR inhibitor), in children with progressive low-grade gliomas who
have failed initial conventional treatment. In addition to evaluating the toxicity of this
drug regimen, the potential efficacy of the regimen will be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Roger Packer
Collaborators:
Children's National Research Institute Children's Research Institute